The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (The ADORE).
Yong Sang Hong
No relevant relationships to disclose
Byung-Ho Nam
No relevant relationships to disclose
Kyu-Pyo Kim
No relevant relationships to disclose
Jae-Lyun Lee
No relevant relationships to disclose
Joon Oh Park
No relevant relationships to disclose
Young Suk Park
No relevant relationships to disclose
Sun Young Kim
No relevant relationships to disclose
Tae-You Kim
No relevant relationships to disclose
Jee Hyun Kim
No relevant relationships to disclose
Joong Bae Ahn
No relevant relationships to disclose
Kyung Hae Jung
No relevant relationships to disclose
Tae Won Kim
No relevant relationships to disclose